...
首页> 外文期刊>Antimicrobial Resistance and Infection Control >Enhanced bactericidal effect of ceftriaxone drug encapsulated in nanostructured lipid carrier against gram-negative Escherichia coli bacteria: drug formulation, optimization, and cell culture study
【24h】

Enhanced bactericidal effect of ceftriaxone drug encapsulated in nanostructured lipid carrier against gram-negative Escherichia coli bacteria: drug formulation, optimization, and cell culture study

机译:增强头孢曲松药物包封在纳米结构脂质载体中的杀菌作用对革兰氏阴性大肠杆菌细菌:药物制剂,优化和细胞培养研究

获取原文

摘要

Ceftriaxone is one of the most common types of antibiotics used to treat most deadly bacterial infections. One way to alleviate the side effects of medication is to reduce drug consumption by changing the ordinary drug forms into nanostructured forms. In this study, a nanostructured lipid carrier (NLC) containing hydrophilic ceftriaxone sodium drug is developed, and its effect on eliminating gram-negative bacteria Escherichia coli death is investigated. Double emulsion solvent evaporation method is applied to prepare NLC. Mathematical modeling based on the solubility study is performed to select the best materials for NLC preparation. Haftyzer-Van Krevelen and Hoy’s models are employed for this purpose. Drug release from optimized NLC is examined under in vitro environment. Then, the efficacy of the optimized sample on eliminating gram-negative bacteria Escherichia coli is investigated. Mathematical modeling reveals that both methods are capable of predicting drug encapsulation efficiency trends by chaining solid and liquid lipids. However, Haftyzer-Van Krevelen’s method can precisely predict the particle size trend by changing the surfactant types in water and oily phases of emulsions. The optimal sample has a mean particle size of 86?nm and drug entrapment efficiency of 83%. Also, a controlled drug release in prepared nanostructures over time is observed under in-vitro media. The results regarding the effectiveness of optimized NLC in killing Escherichia coli bacteria suggests that by cutting drug dosage of the nanostructured form in half, an effect comparable to that of free drug can be observed at longer times. Results confirm that NLC structure is an appropriate alternative for the delivery of ceftriaxone drug with a controlled release behavior.
机译:头孢曲松是用于治疗大多数致命细菌感染的最常见类型的抗生素之一。缓解药物副作用的一种方法是通过将普通药物形式改变为纳米结构形式来减少药物消耗。在该研究中,纳米结构脂质载体(NLC)含有亲水性头孢菌钠药物,研究了对消除革兰氏阴性细菌大肠杆菌死亡的影响。施加双乳液溶剂蒸发方法制备NLC。进行基于溶解度研究的数学建模,以选择用于NLC制剂的最佳材料。 Haftyzer-van Krevelen和Hoy的型号用于此目的。在体外环境下检查来自优化NLC的药物释放。然后,研究了优化样品对消除革兰氏阴性细菌大肠杆菌的功效。数学建模显示,两种方法都能够通过链接固体和液体脂质来预测药物包封效率趋势。然而,Haftyzer-van Krevelen的方法可以通过改变水和油性阶段的水和油性相的表面活性剂类型来精确地预测粒径趋势。最佳样品的平均粒径为86Ω,药物夹带效率为83%。此外,在体外培养基下观察到随时间的制备的纳米结构中的受控药物释放。关于杀灭大肠杆菌细菌的优化NLC有效性的结果表明,通过将纳米结构形式的药物剂量切成两半,可以在更长的时间内观察到与游离药物的效果相当。结果证实,NLC结构是一种适当的替代品,用于使用受控释放行为递送头孢曲松药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号